Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery

NCT01153698 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01153698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01153698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Cohort Study to Evaluate the Safety and Efficacy of Switching From Lovenox (Enoxaparin) 40mg to Pradaxa (Dabigatran Etexilate) 220mg in Patients Undergoing Elective Total Hip or Knee Replacement Surgery
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Terminated
Start date
August 31, 2010
Completion date
December 21, 2011
Enrollment
167 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

arthroplasty, replacement, venous thromboembolism